Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
BMJ Open. 2021 Jan 5;11(1):e042008. doi: 10.1136/bmjopen-2020-042008.
In December 2019, the first cases of COVID-19 associated with SARS-CoV-2 viral infection were described in Wuhan, Hubei Province, China. Since then, it has spread rapidly affecting 188 countries and was declared a pandemic by the WHO on 11 March 2020. Preliminary reports suggest up to 30% of patients require intensive care unit (ICU) admission and case fatality rate estimate is 2.3%-7.2%. The primary reason for ICU admission is hypoxaemic respiratory failure, while factors associated with ICU admission include increased age, presence of comorbidities and cytokine storm. Case series and retrospective trials initially assessed proposed treatments with randomised controlled trials now reporting early outcomes. We conduct a systematic review and meta-analysis to identify epidemiological factors, treatments and complications that predict mortality among critically ill patients with COVID-19.
Our comprehensive search strategy was developed in consultation with a research librarian. We will search electronic databases: Ovid Medline, Ovid Embase, Ovid Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Wiley Cochrane Library. The search strategy combines concepts from COVID-19, validated COVID-19 search filters and geographical locations of large outbreaks. Citation screening, selection, quality assessment and data abstraction will be performed in duplicate. Clinically homogenous epidemiological characteristics, interventions and complications will be pooled in statistical meta-analysis. Within the framework of a living systematic review, the search and data analysis will be updated every 6 months.
Our systematic review will synthesise literature on risk factors and interventions associated with mortality in critically ill patients with COVID-19. Results will be presented at national and international conferences and submitted for peer-reviewed publication. The pooled analysis can provide guidance to inform clinical guidelines for care of critically ill patients with COVID-19. Iterative updates will be made public through open access. Research ethics approval is not required.
CRD42020176672.
2019 年 12 月，在中国湖北省武汉市首次描述了与 SARS-CoV-2 病毒感染相关的 COVID-19 病例。自那时以来，它迅速传播，影响了 188 个国家，并于 2020 年 3 月 11 日被世界卫生组织宣布为大流行。初步报告表明，多达 30%的患者需要入住重症监护病房（ICU），病死率估计为 2.3%-7.2%。入住 ICU 的主要原因是低氧性呼吸衰竭，而与 ICU 入住相关的因素包括年龄增加、合并症和细胞因子风暴。病例系列和回顾性试验最初评估了随机对照试验中提出的治疗方法，现在报告了早期结果。我们进行了系统评价和荟萃分析，以确定预测 COVID-19 重症患者死亡率的流行病学因素、治疗方法和并发症。
我们的全面检索策略是与研究图书馆员协商制定的。我们将在电子数据库中进行搜索：Ovid Medline、Ovid Embase、Ovid 护理和联合健康文献累积索引（CINAHL）和 Wiley Cochrane 图书馆。该搜索策略结合了 COVID-19 的概念、经过验证的 COVID-19 搜索过滤器以及大流行的地理位置。引文筛选、选择、质量评估和数据提取将重复进行。具有临床同质性的流行病学特征、干预措施和并发症将进行统计学荟萃分析。在实时系统评价的框架内，将每 6 个月更新一次搜索和数据分析。
我们的系统评价将综合关于 COVID-19 重症患者死亡率相关风险因素和干预措施的文献。结果将在国家和国际会议上展示，并提交给同行评审出版物。汇总分析可为指导 COVID-19 重症患者的临床指南提供信息。通过开放获取发布迭代更新。不需要进行研究伦理审查。
PROSPERO 注册号：CRD42020176672。
